Arcellx, Inc.
Rare disease drugmaker · part of Gilead Sciences · based in United States · kitepharma.com
Arcellx, Inc. works on 3 rare diseases we track, including Acute Myeloid Leukemia, Multiple Myeloma and 1 more. It has 4 active clinical trials, though none are looking for new volunteers right now.
Arcellx is a cell therapy company that developed anitocabtagene autoleucel (anito-cel), an investigational CAR T-cell therapy for multiple myeloma. Gilead Sciences completed its purchase of Arcellx on April 28, 2026, and anito-cel is now developed by Kite, Gilead's cell therapy company. The FDA is reviewing anito-cel for adults whose multiple myeloma has come back or stopped responding after earlier treatment, with a decision due December 23, 2026.
Arcellx, Inc. pipeline
Each row lists the diseases Arcellx, Inc. is studying at that stage, from the ones closest to approval down to the earliest work.
Arcellx, Inc. clinical trials
These are Arcellx, Inc. trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
4 trials underway, not taking new volunteers
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
Tests SPRX002, ARC-T Cells, Cyclophosphamide, Fludarabine
For Acute Myeloid Leukemia and Myelodysplastic Syndromes
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Tests Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
For Multiple Myeloma
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Tests anitocabtagene-autoleucel
For Multiple Myeloma
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Tests anitocabtagene-autoleucel
For Relapsed and Refractory Multiple Myeloma
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Arcellx, Inc.. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Acute Myeloid Leukemia. Turn any of these off from the link in every email.
More about Arcellx, Inc.
As a rare disease specialist, Arcellx, Inc. has active clinical trial programs and drug development efforts across 3 rare diseases, including Acute Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndromes. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Arcellx, Inc., sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Arcellx, Inc. is headquartered in United States, a subsidiary of Gilead Sciences. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Where Arcellx, Inc. trials take place
The trials above run at 144 study sites in 15 countries. Tap a country to see its states, cities and hospitals.
Rare diseases Arcellx, Inc. works on
Each disease page lists every open trial, not only Arcellx, Inc.'s, plus approved treatments.
Acute myeloid leukemia (AML) is a fast-growing cancer of the bone marrow in which immature white blood cells called blasts crowd out normal blood cells, causing fatigue, infections and bleeding...
How common: The National Cancer Institute's SEER program estimates 22,720 new US cases and 11,500 deaths in 2026, about 1.1% of new cancers, and 83,311 people were living with AML in 2023
Multiple myeloma is a cancer of plasma cells, the white blood cells that make antibodies.
How common: About 36,000 new US diagnoses expected in 2026 and roughly 203,000 people living with it, which puts myeloma right at the edge of the US rare disease threshold; it is 1.7% of all new cancers (NCI SEER)
Myelodysplastic syndromes are a group of blood cancers in which the bone marrow fails to produce enough healthy blood cells.
How common: 10,000 to 15,000 new cases annually in the U.S.; estimated 60,000 to 170,000 Americans living with MDS
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Arcellx, Inc.'s own site is kitepharma.com, and our help paying for treatment page lists drugmaker programs and charity funds.
- NCI SEER Cancer Stat Facts: Acute Myeloid LeukemiaAcute Myeloid Leukemia
- NCI PDQ: Acute Myeloid Leukemia Treatment, patient versionAcute Myeloid Leukemia
- NCI SEER - Cancer Stat Facts: MyelomaMultiple Myeloma
- NCI PDQ - Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment, Patient VersionMultiple Myeloma
- MDS FoundationMyelodysplastic Syndromes
- AAMDS International FoundationMyelodysplastic Syndromes